4.7 Article

Investigation of the Anti-Inflammatory Activity of Fusaproliferin Analogues Guided by Transcriptome Analysis

期刊

FRONTIERS IN PHARMACOLOGY
卷 13, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.881182

关键词

Fusarium proliferatum; fusaproliferin analogues; anti-inflammatory activity; transcriptome analysis; surface plasmon resonance assays

资金

  1. National Natural Science Foundation of China [81673460, 81973460, U19A2011, 82172723]
  2. Department of Science and Technology of Sichuan Province [2021YFN0134, 2021ZYD0079]
  3. Chengdu University of Traditional Chinese Medicine [CZYJC1905, 2020XSGG016, 2020JCR006, SKL2021-19, SKL2021-42]

向作者/读者索取更多资源

It has been found that fusaproliferin and its analogs have anti-inflammatory activity and can serve as new compounds for the treatment of inflammation-related diseases. These compounds exert their anti-inflammatory effects by regulating the activity of key proteins in related signaling pathways, as demonstrated by experimental verification and molecular docking analysis.
Background: Excessive inflammation results in severe tissue damage as well as serious acute or chronic disorders, and extensive research has focused on finding new anti-inflammatory hit compounds with safety and efficacy profiles from natural products. As promising therapeutic entities for the treatment of inflammation-related diseases, fusaproliferin and its analogs have attracted great interest. However, the underlying anti-inflammatory mechanism is still poorly understood and deserves to be further investigated. Methods: For the estimation of the anti-inflammatory activity of fusaproliferin (1) and its analogs (2-4) in vitro and in vivo, lipopolysaccharide (LPS)-induced RAW264.7 macrophages and zebrafish embryos were employed. Then, transcriptome analysis was applied to guide subsequent western blot analysis of critical proteins in related signaling pathways. Surface plasmon resonance assays (SPR) combined with molecular docking analyses were finally applied to evaluate the affinity interactions between 1-4 and TLR4 and provide a possible interpretation of the downregulation of related signaling pathways. Results: 1-4 significantly attenuated the production of inflammatory messengers, including nitric oxide (NO), reactive oxygen species (ROS), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-alpha), and interleukin-1 beta (IL-1 beta), as well as nitric oxide synthase (iNOS) andcyclooxygenase2 (COX-2), in LPS-induced RAW264.7 macrophages. Transcriptome analyses based on RNA-seq indicated the ability of compound 1 to reverse LPS stimulation and the nuclear factor kappa-B (NF-kappa B) and mitogen-activated protein kinase (MAPKs) signaling pathways contribute to the anti-inflammatory process. Experimental verification at the protein level revealed that 1 can inhibit the activation of inhibitor of NF-kappa B kinase (IKK), degradation of inhibitor of NF-kappa B (I.B), and phosphorylation of NF-kappa B and reduce nuclear translocation of NF kappa B. 1 also decreased the phosphorylation of MAPKs, including p38, extracellular regulated protein kinases (ERK), and c-Jun N-terminal kinase (JNK). SPR assays andmolecular docking results indicated that 1-4 exhibited affinity for the TLR4 protein with KD values of 23.5-29.3 mu M. Conclusion: Fusaproliferin and its analogs can be hit compounds for the treatment of inflammation-associated diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据